Literature DB >> 19919770

Prevalence of human T-cell lymphotropic virus type 1 infection in hospitalized patients with tuberculosis.

M de Lourdes Bastos1, B Osterbauer, D L Mesquita, C A Carrera, M J Albuquerque, L Silva, D N Pereira, L Riley, E M Carvalho.   

Abstract

OBJECTIVE: Reports have suggested that human T-cell lymphotropic virus type 1 (HTLV-1) may influence immunological response and therefore the clinical course of tuberculosis (TB) in co-infected individuals. We wished to determine the prevalence of HTLV-1 infection among hospitalized patients in Salvador, Brazil, a region endemic for both HTLV-1 infection and latent TB infection.
DESIGN: A cross-sectional study was conducted at a pulmonary disease hospital between 1 September 2006 and 31 August 2007. Study participants were interviewed and tested for HTLV-1 infection and current or past episode of TB.
RESULTS: Of 607 participants recruited into the study, 360 (59.3%) had a current or past history of TB and 50 (8.2%) had HTLV-1 infection; 39 (6.4%) had both. After controlling for confounding variables, we found that the odds of patients with a positive HTLV-1 test having TB were 2.6 times the odds in those who tested negative for HTLV-1 infection (95%CI 1.2-5.4).
CONCLUSION: In a region endemic for both TB and HTLV-1 infection, HTLV-1 infection increases the risk of Mycobacterium tuberculosis infection. Such a risk may influence TB transmission and the epidemiology of the disease in this community.

Entities:  

Mesh:

Year:  2009        PMID: 19919770      PMCID: PMC2963180     

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  21 in total

1.  HTLV-I in the general population of Salvador, Brazil: a city with African ethnic and sociodemographic characteristics.

Authors:  Inês Dourado; Luiz C J Alcantara; Maurício L Barreto; Maria da Gloria Teixeira; Bernardo Galvão-Castro
Journal:  J Acquir Immune Defic Syndr       Date:  2003-12-15       Impact factor: 3.731

2.  Human alveolar T lymphocyte responses to Mycobacterium tuberculosis antigens: role for CD4+ and CD8+ cytotoxic T cells and relative resistance of alveolar macrophages to lysis.

Authors:  J S Tan; D H Canaday; W H Boom; K N Balaji; S K Schwander; E A Rich
Journal:  J Immunol       Date:  1997-07-01       Impact factor: 5.422

3.  Distribution of human T-lymphotropic virus type I among blood donors: a nationwide Brazilian study.

Authors:  B Galvão-Castro; L Loures; L G Rodriques; A Sereno; O C Ferreira Júnior; L G Franco; M Muller; D A Sampaio; A Santana; L M Passos; F Proietti
Journal:  Transfusion       Date:  1997-02       Impact factor: 3.157

4.  Peripheral blood mononuclear cells from individuals infected with human T-cell lymphotropic virus type 1 have a reduced capacity to respond to recall antigens.

Authors:  Rita Elizabeth Mascarenhas; Cláudia Brodskyn; Geisa Barbosa; Jorge Clarêncio; Antônio Souza Andrade-Filho; Frederico Figueiroa; Bernardo Galvão-Castro; Fernanda Grassi
Journal:  Clin Vaccine Immunol       Date:  2006-05

5.  Co-Infection of Tuberculosis and HIV/HTLV Retroviruses: Frequency and Prognosis Among Patients Admitted in a Brazilian Hospital.

Authors: 
Journal:  Braz J Infect Dis       Date:  1997-03       Impact factor: 1.949

6.  Induction of in vitro human macrophage anti-Mycobacterium tuberculosis activity: requirement for IFN-gamma and primed lymphocytes.

Authors:  M G Bonecini-Almeida; S Chitale; I Boutsikakis; J Geng; H Doo; S He; J L Ho
Journal:  J Immunol       Date:  1998-05-01       Impact factor: 5.422

7.  Modulation of T-cell responses to a recall antigen in human T-cell leukemia virus type 1-infected individuals.

Authors:  M Suzuki; C S Dezzutti; A Okayama; N Tachibana; H Tsubouchi; N Mueller; R B Lal
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

8.  HTLV-1 decreases Th2 type of immune response in patients with strongyloidiasis.

Authors:  A F Porto; F A Neva; H Bittencourt; W Lisboa; R Thompson; L Alcântara; E M Carvalho
Journal:  Parasite Immunol       Date:  2001-09       Impact factor: 2.280

Review 9.  [Clinical and immunological consequences of the association between HTLV-1 and strongyloidiasis].

Authors:  Maria Aurélia F Porto; André Muniz; Jamary Oliveira Júnior; Edgar Marcelino Carvalho
Journal:  Rev Soc Bras Med Trop       Date:  2003-02-26       Impact factor: 1.581

10.  Strongyloides stercoralis hyperinfection associated with human T cell lymphotropic virus type-1 infection in Peru.

Authors:  E Gotuzzo; A Terashima; H Alvarez; R Tello; R Infante; D M Watts; D O Freedman
Journal:  Am J Trop Med Hyg       Date:  1999-01       Impact factor: 2.345

View more
  11 in total

1.  Association of Tuberculosis Status with Neurologic Disease and Immune Response in HTLV-1 Infection.

Authors:  Anselmo Souza; Natália Carvalho; Yuri Neves; Silvane Braga Santos; Maria de Lourdes Bastos; Sérgio Arruda; Eduardo Martins Netto; Marshall J Glesby; Edgar Carvalho
Journal:  AIDS Res Hum Retroviruses       Date:  2017-06-26       Impact factor: 2.205

2.  Evaluation of the microbicidal activity and cytokines/chemokines profile released by neutrophils from HTLV-1-infected individuals.

Authors:  Caroline A Bezerra; Thiago M Cardoso; Angela Giudice; Aurélia F Porto; Silvane B Santos; Edgar M Carvalho; Olívia Bacellar
Journal:  Scand J Immunol       Date:  2011-09       Impact factor: 3.487

3.  Prevalence of HTLV-I Infection and Its Association with Tuberculosis among Patients at an Urban Clinic in Haiti.

Authors:  Kathleen F Walsh; Myung Hee Lee; Josef A Brejt; Mary J Reust; Marc Jean Juste; Genevieve Hilaire; Jean William Pape; Serena Koenig; Kathryn Dupnik
Journal:  Am J Trop Med Hyg       Date:  2022-03-14       Impact factor: 3.707

4.  Impairment of the humoral and CD4(+) T cell responses in HTLV-1-infected individuals immunized with tetanus toxoid.

Authors:  Anselmo Souza; Silvane Santos; Lucas P Carvalho; Maria Fernanda R Grassi; Edgar M Carvalho
Journal:  Hum Immunol       Date:  2016-06-06       Impact factor: 2.850

5.  Functional activity of monocytes and macrophages in HTLV-1 infected subjects.

Authors:  Camila F Amorim; Anselmo S Souza; Angela G Diniz; Natália B Carvalho; Silvane B Santos; Edgar M Carvalho
Journal:  PLoS Negl Trop Dis       Date:  2014-12-18

6.  Tuberculosis incidence in a cohort of individuals infected with human T-lymphotropic virus type 1 (HTLV-1) in Salvador, Brazil.

Authors:  Maria Fernanda Rios Grassi; Normeide Pedreira Dos Santos; Monique Lírio; Afrânio Lineu Kritski; Maria da Conceição Chagas Almeida; Leonardo Pereira Santana; Noilson Lázaro; Juarez Dias; Eduardo Martins Netto; Bernardo Galvão-Castro
Journal:  BMC Infect Dis       Date:  2016-09-19       Impact factor: 3.090

Review 7.  Human T Lymphotropic Virus and Pulmonary Diseases.

Authors:  Apio R N Dias; Luiz F M Falcão; Aline S C Falcão; Valéria M F Normando; Juarez A S Quaresma
Journal:  Front Microbiol       Date:  2018-08-14       Impact factor: 5.640

Review 8.  Human T-cell leukaemia virus type 1 associated pulmonary disease: clinical and pathological features of an under-recognised complication of HTLV-1 infection.

Authors:  Lloyd Einsiedel; Fabian Chiong; Hubertus Jersmann; Graham P Taylor
Journal:  Retrovirology       Date:  2021-01-06       Impact factor: 4.602

9.  Influence of HTLV-1 on the clinical, microbiologic and immunologic presentation of tuberculosis.

Authors:  Maria de Lourdes Bastos; Silvane B Santos; Anselmo Souza; Brooke Finkmoore; Ohana Bispo; Tasso Barreto; Ingrid Cardoso; Iana Bispo; Flávia Bastos; Daniele Pereira; Lee Riley; Edgar M Carvalho
Journal:  BMC Infect Dis       Date:  2012-08-28       Impact factor: 3.090

10.  Prevalence and genetic characterisation of HTLV-1 and 2 dual infections in patients with pulmonary tuberculosis in Central-West Brazil.

Authors:  Aline Garcia Kozlowski; Megmar Aparecida dos Santos Carneiro; Márcia Alves Dias de Matos; Sheila Araújo Teles; João Alves Filho Araújo; Koko Otsuki; Ana Carolina Paulo Vicente; Regina Maria Bringel Martins
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-10-09       Impact factor: 2.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.